Aaron D Gitler Selected Research

polyglutamine

7/2014	A cellular system that degrades misfolded proteins and protects against neurodegeneration.
4/2014	Evaluating noncoding nucleotide repeat expansions in amyotrophic lateral sclerosis.
7/2012	ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.
1/2012	The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect.
11/2011	Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS.
3/2011	PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats.
8/2010	Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.
4/2008	A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aaron D Gitler Research Topics

Disease

22	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 07/2006
22	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2022 - 04/2008
14	Parkinson Disease (Parkinson's Disease) 01/2019 - 07/2006
8	Frontotemporal Dementia (Semantic Dementia) 01/2022 - 07/2009
6	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 07/2014 - 08/2010
5	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 04/2010
5	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 06/2012 - 04/2008
4	Proteostasis Deficiencies 07/2014 - 01/2008
3	Huntington Disease (Huntington's Disease) 04/2016 - 04/2010
2	Disease Progression 01/2020 - 01/2017
2	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 01/2017 - 11/2011
2	TDP-43 Proteinopathies 01/2017 - 01/2016
2	Sarcoma (Soft Tissue Sarcoma) 01/2016 - 11/2011
1	Polyps 01/2022
1	Dehydration (Water Stress) 01/2021
1	Hypoxia (Hypoxemia) 01/2017
1	Starvation 01/2017
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2017
1	Liver Diseases (Liver Disease) 01/2017
1	Hepatomegaly 01/2017
1	Cholestasis 01/2017
1	Wounds and Injuries (Trauma) 01/2017
1	Inflammation (Inflammations) 11/2016
1	Multiple System Atrophy 09/2014
1	Generalized Epilepsy 08/2014
1	Muscular Dystrophies (Muscular Dystrophy) 08/2014
1	Walker-Warburg Syndrome 08/2014
1	Neuromuscular Diseases (Neuromuscular Disease) 04/2014
1	Ewing Sarcoma (Sarcoma, Ewing) 07/2012
1	Cerebellar Ataxia (Dysmetria) 01/2012
1	Motor Neuron Disease (Primary Lateral Sclerosis) 01/2012
1	Fragile X Syndrome (Martin Bell Syndrome) 11/2011
1	Parkinsonian Disorders (Parkinsonism) 03/2011
1	Brain Diseases (Brain Disorder) 04/2010
1	Synucleinopathies 09/2008
1	Cardiomegaly (Heart Hypertrophy) 09/2003
1	Heart Failure 09/2003
1	Hypertrophy 09/2003

Drug/Important Bio-Agent (IBA)

22	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2008
11	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2022 - 04/2010
9	Ataxin-2IBA 01/2018 - 08/2010
8	PrionsIBA 01/2021 - 04/2010
8	polyglutamineIBA 07/2014 - 04/2008
7	alpha-SynucleinIBA 01/2019 - 07/2006
5	SynucleinsIBA 04/2016 - 09/2008
4	RNA (Ribonucleic Acid)IBA 01/2018 - 06/2012
4	Amyloid (Amyloid Fibrils)IBA 04/2016 - 07/2009
2	NucleotidesIBA 01/2019 - 04/2014
2	Protein AggregatesIBA 01/2018 - 01/2017
2	EnzymesIBA 01/2017 - 01/2017
2	Peptides (Polypeptides)IBA 04/2016 - 04/2010
2	Phosphotransferases (Kinase)IBA 01/2016 - 04/2010
2	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2016 - 04/2008
1	PolymersIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Apolipoproteins E (ApoE)IBA 01/2022
1	PolyphosphatesIBA 01/2022
1	Ribosomal Proteins (Ribosomal Protein)IBA 01/2019
1	HydrogelsIBA 01/2018
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2018
1	DipeptidesIBA 01/2018
1	MicroRNAs (MicroRNA)IBA 01/2017
1	PhosphofructokinasesIBA 01/2017
1	AMP-Activated Protein KinasesIBA 01/2017
1	aspartyl- arginyl- valyl- tyrosyl- isoleucyl- histidyl- prolyl- phenylalanyl- histidyl- leucyl- valyl- isoleucyl- histidine (hTDP)IBA 01/2016
1	Nuclear Proteins (Protein, Nuclear)IBA 01/2016
1	Dystroglycans (Dystroglycan)IBA 08/2014
1	Ion Channels (Ion Channel)IBA 08/2014
1	Profilins (Profilin)IBA 06/2014
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 03/2013
1	Amino Acids FDA Link 03/2013
1	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 03/2013
1	RNA-Binding Protein EWSIBA 07/2012
1	ManganeseIBA 01/2012
1	Levodopa (L Dopa)FDA LinkGeneric 01/2012
1	angiogeninIBA 11/2011
1	DNA (Deoxyribonucleic Acid)IBA 11/2011
1	Codon (Codons)IBA 03/2011
1	Prion ProteinsIBA 04/2010
1	Leucine (L-Leucine)FDA Link 04/2010
1	UbiquitinIBA 04/2008
1	Histone Deacetylase InhibitorsIBA 09/2003
1	Histone Deacetylases (Histone Deacetylase)IBA 09/2003
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 09/2003
1	trichostatin A (A 300)IBA 09/2003
1	Homeodomain Proteins (Proteins, Homeobox)IBA 09/2003

Therapy/Procedure

2	Therapeutics 01/2017 - 01/2017